… Suchard, Immunology and Inflammation Drug Discovery, Bristol-Myers Squibb Pharmaceutical
Research … E-mail: suzanne.suchard@bms.com Accepted for publication July 5, 2007. …

Bacterial adherence to surfaces is the determining first step in staphylococcal infections.
Activated platelets mediate adherence of staphylococci to tissues during inflammation or …

Agents targeting the PD1–PDL1 axis have transformed cancer therapy. Factors that influence
clinical response to PD1–PDL1 inhibitors include tumor mutational burden, immune …

Background. The selective inhibitor of T-cell costimulation, belatacept, blocks CD28-mediated
T-cell activation by binding CD80 and CD86 on antigen-presenting cells. Understanding …

B94 was originally described as a novel tumor necrosis factor-alpha-inducible primary response
gene in endothelial cells which was also induced in an in vitro model of angiogenesis. …

Mounting evidence in models of both autoimmunity and chronic viral infection suggests that
the outcome of T cell activation is critically impacted by the constellation of co-stimulatory …

Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disease driven by
both innate and adaptive immune cells. African Americans tend to present with more severe …

The cytosolic portion of CD45, a major transmembrane glycoprotein found on nucleated
hematopoietic cells, contains protein tyrosine phosphatase activity and is critical for T-cell …

The presence of the extracellular matrix protein thrombospondin (TSP) at sites of tissue injury
or inflammation may promote monocyte migration to these sites and play a central role in …

Targeting the CD28-CD80/86 pathway with an anti-CD28 antagonist is a promising alternative
to current therapies for autoimmunity. However, attempts at generating conventional anti-…